Amprius Technologies: Analyst Views and Financial Trajectory

JL Collins

Author of "The Simple Path to Wealth," a straightforward guide to stock market investing and financial independence.

In the recent quarter, Amprius Technologies (AMPX) has garnered diverse opinions from financial analysts, presenting a blend of positive and cautious outlooks. The company's average price target has risen substantially, suggesting an overall positive sentiment among experts. This comprehensive review examines the most recent analyst evaluations and crucial financial indicators for Amprius Technologies, shedding light on its market standing and operational performance.

A detailed examination of recent analyst activities reveals the perception of Amprius Technologies within the financial community. Four analysts have weighed in, with varying perspectives on the company's prospects. The 12-month price targets provided by these analysts offer further clarity, with an average target of $19.25. The highest estimate stands at $20.00, while the lowest is $17.00. This upward trend is notable, as the current average represents a 20.31% increase from the prior average price target of $16.00.

For instance, Derek Soderberg from Cantor Fitzgerald and Chip Moore from Roth Capital both raised their ratings to 'Overweight' and 'Buy' respectively, increasing their price targets to $20.00 from $16.00. Additionally, Eric Stine of Craig-Hallum and Austin Bohlig of Needham initiated coverage with 'Buy' ratings and price targets of $17.00 and $20.00, respectively. These adjustments signify analysts' reactions to market shifts and the company's recent performance.

Amprius Technologies, a company dedicated to producing silicon anodes for high-energy-density lithium-ion batteries, focuses on mobility applications across aviation, electric vehicles (EVs), and light electric vehicles (LEVs). Their batteries are vital for both current and emerging aerial technologies, including unmanned aerial systems like drones and high-altitude pseudo-satellites.

From a financial standpoint, Amprius Technologies exhibits a market capitalization that is comparatively smaller than its industry counterparts, potentially influenced by its perceived growth potential or operational scale. However, the company demonstrated robust revenue growth, achieving a remarkable 172.77% increase as of September 30, 2025, outperforming its peers in the Industrials sector. Despite this impressive revenue growth, the company faces challenges in profitability, indicated by a net margin of -18.16%, which lags behind industry averages and points to potential cost management issues. Similarly, both Return on Equity (ROE) at -4.33% and Return on Assets (ROA) at -2.78% are below industry benchmarks, suggesting difficulties in efficiently utilizing capital and assets to generate shareholder returns. Nevertheless, Amprius Technologies maintains a healthy financial structure with a debt-to-equity ratio of 0.37, which is lower than industry norms.

Analysts, as specialists in banking and finance, typically provide assessments for specific stocks or sectors. Their evaluations are based on thorough research of company financial statements, participation in conference calls, meetings, and discussions with industry insiders. While analyst ratings are typically updated quarterly and often include predictions for metrics like growth estimates and earnings, it is crucial for investors to remember that these are expert opinions and not infallible forecasts.

In summary, while Amprius Technologies shows strong revenue growth and a sound financial structure concerning debt, it faces hurdles in profitability and capital efficiency. The recent analyst upgrades and increased price targets reflect a growing optimism regarding the company's future, indicating a potential positive trajectory despite current challenges in certain financial metrics.

you may like

youmaylikeicon
Southern Stock: A Deep Dive Into Analyst Perspectives (13 Ratings)

Southern Stock: A Deep Dive Into Analyst Perspectives (13 Ratings)

By Ramit Sethi
Market Dynamics: Oil Surges, Retail Sales Dip, and Global Equities Fluctuate

Market Dynamics: Oil Surges, Retail Sales Dip, and Global Equities Fluctuate

By Bola Sokunbi
TrueShares CEO Sees Autocallable ETFs as the Next Major Income Trade as Assets Approach $1 Billion

TrueShares CEO Sees Autocallable ETFs as the Next Major Income Trade as Assets Approach $1 Billion

By Vicki Robin
Truist Upgrades Price Target for CoreWeave (CRWV) to $85, Maintains Hold Rating

Truist Upgrades Price Target for CoreWeave (CRWV) to $85, Maintains Hold Rating

By Vicki Robin
Reitar Logtech Holdings Soars on $60 Million Strategic Investment

Reitar Logtech Holdings Soars on $60 Million Strategic Investment

By T. Harv Eker
Stock Market Experiences Fluctuations Amid Geopolitical Tensions and Economic Reports

Stock Market Experiences Fluctuations Amid Geopolitical Tensions and Economic Reports

By T. Harv Eker
Korn Ferry Expected to Announce Strong Q3 Earnings; Analysts Adjust Price Targets

Korn Ferry Expected to Announce Strong Q3 Earnings; Analysts Adjust Price Targets

By Natalie Pace
BioXcel Therapeutics Stock Declines Despite Positive Opioid Withdrawal Drug Trial Results

BioXcel Therapeutics Stock Declines Despite Positive Opioid Withdrawal Drug Trial Results

By Bola Sokunbi
Technology and Biotech Lead as US Stocks Show Mixed Performance

Technology and Biotech Lead as US Stocks Show Mixed Performance

By Ramit Sethi
Unlocking Wealth: Warren Buffett's Dividend Strategy for Financial Growth

Unlocking Wealth: Warren Buffett's Dividend Strategy for Financial Growth

By Bola Sokunbi
Greencoat UK Wind's Resilience Amidst Sector Headwinds

Greencoat UK Wind's Resilience Amidst Sector Headwinds

By Bola Sokunbi
BigCommerce Strategic Shift: AI, Monetization, and Platform Evolution

BigCommerce Strategic Shift: AI, Monetization, and Platform Evolution

By Vicki Robin
Amending Your Tax Return: A Comprehensive Guide to Form 1040-X

Amending Your Tax Return: A Comprehensive Guide to Form 1040-X

By Mr. Money Mustache
South Bow Reports Robust Q4 and Full-Year 2025 Financial Results and Operational Milestones

South Bow Reports Robust Q4 and Full-Year 2025 Financial Results and Operational Milestones

By T. Harv Eker
RBC Capital Adjusts Price Target for Viridian Therapeutics to $42, Maintains Outperform Rating

RBC Capital Adjusts Price Target for Viridian Therapeutics to $42, Maintains Outperform Rating

By Dave Ramsey